Hot issues on Chinese expert consensus of prostate cancer management

Abstract

Prostate cancer is one of the most common solid tumors in men, and its incidence continues to rise in China. Several guidelines have been developed and published to facilitate the standardization of diagnosis and treatment of prostate cancer. However, there are still many challenges and issues in clinical practice that lack high-level evidence. A panel of recognized domestic experts including urologists, medical oncologists, and radiologists was organized and invited to discuss and vote on the key issues of lacking high-level evidence and unified guideline recommendations questions. Following careful selection and voting processes, 19 questions were identified, leading to the establishment of a consensus based on collective agreement regarding these hot issues. The aim of this consensus is to provide a reference for managing the whole patient journey of prostate cancer for Chinese clinicians.

Keywords

developmental urology / prostate cancer / urologic oncology

References

[1] Gu XY , Zheng RS , Zhang SW , Zeng HM , Sun KX , Zou XN , et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014. Zhonghua yu fang yi xue za zhi [Chin J Prevent Med]. 2018; 52 (6): 586- 92.

[2] Chen W , Zheng R , Baade PD , Zhang S , Zeng H , Bray F , et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66 (2): 115- 32.

[3] Zheng R , Zhang S , Zeng H , Wang S , Sun K , Chen R , et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022; 2 (1): 1- 9.

[4] Huang Q , Zi H , Luo L , Li X , Zhu C , Zeng X . Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030. BMC Cancer. 2022; 22: 1164.

[5] Hugosson J , Roobol MJ , Månsson M , Tammela TLJ , Zappa M , Nelen V , et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019; 76 (1): 43- 51.

[6] Pinsky PF , Miller E , Prorok P , Grubb R , Crawford ED , Andriole G . Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019; 123 (5): 854- 60.

[7] Andriole GL , Crawford ED , Grubb RL , Buys SS , Chia D , Church TR , et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360 (13): 1310- 9.

[8] Andriole GL , Crawford ED , Grubb RL , Buys SS , Chia D , Church TR , et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104 (2): 125- 32.

[9] Van Poppel H , Roobol MJ , Chapple CR , Catto JWF , N'Dow J , Sønksen J , et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021; 80 (6): 703- 11.

[10] Welch HG , Albertsen PC . Reconsidering prostate cancer mortality-the future of PSA screening. N Engl J Med. 2020; 382 (16): 1557- 63.

[11] Catalona WJ . Prostate cancer screening. Med Clin North Am. 2018; 102 (2): 199- 214.

[12] Zhu Y , Mo M , Wei Y , Wu J , Pan J , Freedland SJ , et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021; 18 (5): 282- 301.

[13] He J , Chen WQ , Li N , Cao W , Ye DW , Ma JH , et al. China guideline for the screening and early detection of prostate cancer (2022, Beijing). Zhonghua zhong liu za zhi [Chin J Oncol]. 2022; 44 (1): 29- 53.

[14] Carlsson S , Assel M , Ulmert D , Gerdtsson A , Hugosson J , Vickers A , et al. Screening for prostate cancer starting at age 50-54 years. a population-based cohort study. Eur Urol. 2017; 71 (1): 46- 52.

[15] Liu Y , Xiao G , Zhou JW , Yang JK , Lu L , Bian J , et al. Optimal starting age and baseline level for repeat tests: economic concerns of PSA screening for Chinese men-10-year experience of a single center. Urol Int. 2020; 104 (3-4): 230- 8.

[16] Li X , Tsuji I , Kuwahara M , Zhang H , Wang H , Zhang L , et al. Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol. 2004; 36 (4): 541- 8.

[17] Qin XJ , Gu CY , Ye DW , et al. Research on optimizing Chinese prostate cancer screening project based on health economics evaluation. Health Econ. 2021; 40 (06): 9- 13.

[18] Qin X , Ye D , Gu C , Huang Y , Gu W , Dai B , et al. Prostate cancer screening using prostate-specific antigen tests in a high-risk population in China: a cost-utility analysis. Curr Ther Res. 2021; 95: 100653.

[19] Ye DW , Guo J , He ZS , Qi J , Shi BK , Wei Q , et al. Chinese Society of Clinical Oncology (CSCO) prostate cancer guidelines. 2023.

[20] Chinese Anti-Cancer Association Genitourinary Oncology Committee Prostate Cancer Group. Chinese expert consensus on prostate cancer screening (2021 edition). Chin J Cancer. 2021; 31 (5): 435- 40.

[21] Emmett L , Buteau J , Papa N , Moon D , Thompson J , Roberts MJ , et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021; 80 (6): 682- 9.

[22] Meissner VH , Rauscher I , Schwamborn K , Neumann J , Miller G , Weber W , et al. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography. Eur Urol. 2022; 82 (2): 156- 60.

[23] Yang FY , Li YJ , Han SJ , Chen D , Wu LY , Xiao ZJ , et al. The preliminary clinical study on radical prostatectomy without preoperative prostate biopsy. Zhonghua Yi Xue Za Zhi. 2020; 100 (34): 2658- 62.

[24] Ma SF , Lian ZP , He ZW , et al. Feasibility of radical prostatectomy without biopsy for patients with highly suspected localized prostate cancer diagnosed by mpMRI and 68Ga-PSMA PET/CT. Chin J Urol. 2022; 43 (7): 505- 11.

[25] Jiang X , Liu R , Xu Y . Performing radical prostatectomy for patients with highly suspected prostate cancer without preoperative biopsy: an open label, single-arm clinical study. Eur Urol. 2023; 83 (S1): S1298.

[26] Chinese Urological Association, Chinese Prostate Cancer Consortium. Chinese expert consensus on prostate biopsy (2022 edition). Chin J Urol. 2022; 43 (11): 801- 6.

[27] Hofman MS , Lawrentschuk N , Francis RJ , Tang C , Vela I , Thomas P , et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395 (10231): 1208- 16.

[28] Petersen LJ , Zacho HD . PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020; 20 (1): 10.

[29] Blute ML , Bergstralh EJ , Iocca A , Scherer B , Zincke H . Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001; 165 (1): 119- 25.

[30] Qu M , Lin HZ , Wang HF , et al. Robotic-assisted laparoscopic prostatectomy in patients with high-risk prostate cancer: experiences of 400 cases. Chin J Urol. 2017; 38 (6): 424- 7.

[31] Moreira DM , Presti JC , Aronson WJ , Terris MK , Kane CJ , Amling CL , et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009; 182 (5): 2250- 6.

[32] Moreira DM , Presti JC , Aronson WJ , Terris MK , Kane CJ , Amling CL , et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010; 105 (11): 1541- 7.

[33] Spratt DE , Dai DLY , Den RB , Troncoso P , Yousefi K , Ross AE , et al. Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy. Eur Urol. 2018; 74 (1): 107- 14.

[34] Thompson IM , Tangen CM , Paradelo J , Lucia MS , Miller G , Troyer D , et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival. J Urol. 2009; 181 (3): 956- 62.

[35] Bolla M , Van Poppel H , Tombal B , Vekemans K , Da Pozzo L , de Reijke TM , et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012; 380 (9858): 2018- 27.

[36] Wiegel T , Bartkowiak D , Bottke D , Bronner C , Steiner U , Siegmann A , et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014; 66 (2): 243- 50.

[37] Lott F . Editorial comment: randomised trial of adjuvant radiotherapy following radical pros-tatectomy versus radical prostatectomy alone in prostate cancer patients with posi-tive margins or extracapsular extension. Int Braz J Urol. 2020; 46 (5): 855- 6.

[38] Vale CL , Fisher D , Kneebone A , Parker C , Pearse M , Richaud P , et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020; 396 (10260): 1422- 31.

[39] Pollack A , Karrison TG , Balogh AG , Gomella LG , Low DA , Bruner DW , et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022; 399 (10338): 1886- 901.

[40] Thompson IM , Tangen CM , Paradelo J , Lucia MS , Miller G , Troyer D , et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181: 956- 62.

[41] Bolla M , van Poppel H , Tombal B , Vekemans K , Da Pozzo L , de Reijke TM , et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012; 380: 2018- 27.

[42] Leyh-Bannurah SR , Kachanov M , Karakiewicz PI , Beyersdorff D , Pompe RS , Oh-Hohenhorst SJ , et al. Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. World J Urol. 2021; 39 (1): 81- 8.

[43] Hackman G , Taari K , Tammela TL , Matikainen M , Kouri M , Joensuu T , et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. 2019; 76 (5): 586- 95.

[44] Tilki D , Chen MH , Wu J , Huland H , Graefen M , Wiegel T , et al. Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol. 2021; 39 (20): 2284- 93.

[45] Dorff TB , Flaig TW , Tangen CM , Hussain MHA , Swanson GP , Wood DP , et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011; 29 (15): 2040- 5.

[46] Sato YT , Fukuhara H , Suzuki M , Fujimura T , Nakagawa T , Nishimatsu H , et al. Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 2014; 14: 13.

[47] Schaeffer EM , Srinivas S , Adra N , An Y , Barocas D , Bitting R , et al. Prostate Cancer, Version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2023; 21 (10): 1067- 96.

[48] Tilki D , van den Bergh RCN , Briers E , et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer.. Eur Urol. 2024; S0302-2838 (24): 02306.

[49] Perera M , Papa N , Christidis D , Wetherell D , Hofman MS , Murphy DG , et al. Sensitivity, specificity, and predictors of positive 68 Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016; 70 (6): 926- 37.

[50] Farolfi A , Ceci F , Castellucci P , Graziani T , Siepe G , Lambertini A , et al. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. 2019; 46 (1): 11- 9.

[51] Ceci F , Castellucci P , Graziani T , Farolfi A , Fonti C , Lodi F , et al. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019; 46 (1): 31- 9.

[52] Rauscher I , Düwel C , Haller B , Rischpler C , Heck MM , Gschwend JE , et al. Efficacy, predictive factors, and prediction nomograms for 68 Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol. 2018; 73 (5): 656- 61.

[53] Wondergem M , Jansen BHE , van der Zant FM , van der Sluis TM , Knol RJJ , van Kalmthout LWM , et al. Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 46 (9): 1911- 8.

[54] Mena E , Lindenberg ML , Shih JH , Adler S , Harmon S , Bergvall E , et al. Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2018; 45 (1): 4- 11.

[55] Morigi JJ , Stricker PD , van Leeuwen PJ , Tang R , Ho B , Nguyen Q , et al. Prospective comparison of 18F-fluoromethylcholine versus68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015; 56 (8): 1185- 90.

[56] Afshar-Oromieh A , Zechmann CM , Malcher A , Eder M , Eisenhut M , Linhart HG , et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41 (1): 11- 20.

[57] Caroli P , Sandler I , Matteucci F , De Giorgi U , Uccelli L , Celli M , et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018; 45 (12): 2035- 44.

[58] Rouvière O , Vitry T , Lyonnet D . Imaging of prostate cancer local recurrences: why and how? Eur Radiol. 2010; 20 (5): 1254- 66.

[59] Tendulkar RD , Agrawal S , Gao T , Efstathiou JA , Pisansky TM , Michalski JM , et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016; 34 (30): 3648- 54.

[60] Parker CC , Clarke NW , Cook AD , Kynaston HG , Petersen PM , Catton C , et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020; 396 (10260): 1413- 21.

[61] Kneebone A , Fraser-Browne C , Delprado W , Duchesne G , Fisher R , Frydenberg M , et al. A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP "RAVES" trial. Int J Radiat Oncol Biol Phys. 2019; 105 (1): S37- 8.

[62] Stish BJ , Pisansky TM , Harmsen WS , Davis BJ , Tzou KS , Choo R , et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016; 34 (32): 3864- 71.

[63] Trock BJ . Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299 (23): 2760- 9.

[64] Shipley WU , Seiferheld W , Lukka HR , Major PP , Heney NM , Grignon DJ , et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017; 376 (5): 417- 28.

[65] Carrie C , Magné N , Burban-Provost P , Sargos P , Latorzeff I , Lagrange JL , et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019; 20 (12): 1740- 9.

[66] Kucharczyk MJ , Tsui JMG , Khosrow-Khavar F , Bahoric B , Souhami L , Anidjar M , et al. Combined long-term androgen deprivation and pelvic radiotherapy in the post-operative management of pathologically defined high-risk prostate cancer patients: results of the prospective phase II McGill 0913 study. Front Oncol. 2020; 10: 312.

[67] Boorjian SA , Thompson RH , Tollefson MK , Rangel LJ , Bergstralh EJ , Blute ML , et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011; 59 (6): 893- 9.

[68] Chi KN , Agarwal N , Bjartell A , Chung BH , Pereira de Santana Gomes AJ , Given R , et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019; 381 (1): 13- 24.

[69] Armstrong AJ , Szmulewitz RZ , Petrylak DP , Holzbeierlein J , Villers A , Azad A , et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019; 37 (32): 2974- 86.

[70] Davis ID , Martin AJ , Stockler MR , Begbie S , Chi KN , Chowdhury S , et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019; 381 (2): 121- 31.

[71] Parker CC , James ND , Brawley CD , Clarke NW , Hoyle AP , Ali A , et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018; 392 (10162): 2353- 66.

[72] Bossi A , Foulon S , Maldonado X , Sargos P , McDermott RS , Flechon A , et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Oncol. 2023; 41 ((17 suppl)).

[73] James ND , de Bono JS , Spears MR , Clarke NW , Mason MD , Dearnaley DP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017; 377 (4): 338- 51.

[74] Hoyle AP , Ali A , James ND , Cook A , Parker CC , de Bono JS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. Eur Urol. 2019; 76 (6): 719- 28.

[75] Sweeney CJ , Chen YH , Carducci M , Liu G , Jarrard DF , Eisenberger M , et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373 (8): 737- 46.

[76] Fizazi K , Foulon S , Carles J , Roubaud G , McDermott R , Fléchon A , et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399 (10336): 1695- 707.

[77] Smith MR , Hussain M , Saad F , Fizazi K , Sternberg CN , Crawford ED , et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022; 386 (12): 1132- 42.

[78] Hussain MHA , Tombal BF , Saad F , Fizazi K , Sternberg CN , Crawford ED , et al. Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study. J Clin Oncol. 2023; 41 ((6 suppl)).

[79] Fizazi K , Shore N , Tammela TL , Ulys A , Vjaters E , Polyakov S , et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019; 380 (13): 1235- 46.

[80] Hussain M , Fizazi K , Saad F , Rathenborg P , Shore N , Ferreira U , et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378 (26): 2465- 74.

[81] Smith MR , Saad F , Chowdhury S , Oudard S , Hadaschik BA , Graff JN , et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378 (15): 1408- 18.

[82] Fendler WP , Weber M , Iravani A , Hofman MS , Calais J , Czernin J , et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019; 25 (24): 7448- 54.

[83] Wang B , Liu C , Wei Y , Meng J , Zhang Y , Gan H , et al. A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020; 26 (17): 4551- 8.

[84] Turco F , Gillessen S , Cathomas R , Buttigliero C , Vogl UM . Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Res Rep Urol. 2022; 14: 339- 50.

[85] Loriot Y , Bianchini D , Ileana E , Sandhu S , Patrikidou A , Pezaro C , et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013; 24 (7): 1807- 12.

[86] Noonan KL , North S , Bitting RL , Armstrong AJ , Ellard SL , Chi KN . Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013; 24 (7): 1802- 7.

[87] Schrader AJ , Boegemann M , Ohlmann CH , Schnoeller TJ , Krabbe LM , Hajili T , et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2014; 65 (1): 30- 6.

[88] Schmid SC , Geith A , Böker A , Tauber R , Seitz AK , Kuczyk M , et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv Ther. 2014; 31 (2): 234- 41.

[89] de Bono J , Mateo J , Fizazi K , Saad F , Shore N , Sandhu S , et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020; 382 (22): 2091- 102.

[90] Hussain M , Mateo J , Fizazi K , Saad F , Shore N , Sandhu S , et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020; 383 (24): 2345- 57.

[91] Merseburger AS , Attard G , Åström L , Matveev VB , Bracarda S , Esen A , et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 2022; 23 (11): 1398- 408.

[92] de Bono JS , Logothetis CJ , Molina A , Fizazi K , North S , Chu L , et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364 (21): 1995- 2005.

[93] Fizazi K , Scher HI , Molina A , Logothetis CJ , Chi KN , Jones RJ , et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13 (10): 983- 92.

[94] de Wit R , de Bono J , Sternberg CN , Fizazi K , Tombal B , Wülfing C , et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019; 381 (26): 2506- 18.

[95] Clarke NW , Armstrong AJ , Thiery-Vuillemin A , et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022; 1 (9): EVIDoa2200043.

[96] Li N , Xiao G . Advances in treatment of patients with prostate cancer bone metastases. Cancer Res Prevent Treat. 2020; 47 (8): 641- 6.

[97] Saylor PJ , Smith MR . Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2009; 13 (1): 20- 7.

[98] Berruti A , Dogliotti L , Terrone C , Cerutti S , Isaia G , Tarabuzzi R , et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002; 167 (6): 2361- 7.

[99] Daniell HW , Dunn SR , Ferguson DW , Lomas G , Niazi Z , Stratte PT . Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163 (1): 181- 6.

[100] Brown JE , Handforth C , Compston JE , Cross W , Parr N , Selby P , et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol. 2020; 25 100311.

[101] Huben RP , Murphy GP . Prostate cancer: an update. CA Cancer J Clin. 1986; 36 (5): 274- 92.

[102] Smith MR , Egerdie B , Toriz NH , Feldman R , Tammela TLJ , Saad F , et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361 (8): 745- 55.

[103] Roudier MP , Morrissey C , True LD , Higano CS , Vessella RL , Ott SM . Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008; 180 (3): 1154- 60.

[104] Smith MR , Halabi S , Ryan CJ , Hussain A , Vogelzang N , Stadler W , et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014; 32 (11): 1143- 50.

[105] Wirth M , Tammela T , Cicalese V , Gomez Veiga F , Delaere K , Miller K , et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2015; 67 (3): 482- 91.

[106] Smith MR , Coleman RE , Klotz L , Pittman K , Milecki P , Ng S , et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015; 26 (2): 368- 74.

[107] Henry D , Vadhan-Raj S , Hirsh V , von Moos R , Hungria V , Costa L , et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014; 22 (3): 679- 87.

[108] Chen N , Wang Z , Chen M , Ma Q , He Y , Wang Y , et al. Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer. Cancer Biol Med. 2024; 20 (12): 1047- 59.

RIGHTS & PERMISSIONS

The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.